New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of lifeRESEARCH TRIANGLE...
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology...
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical developmentSOUTH...
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval...
Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan®...
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless...
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two...
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of...
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing...
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused...
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized...
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of...
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnosticsThis partnership...
JOHNSON CITY, Tenn., May 29, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement...
BOSTON, May 29, 2025 /PRNewswire/ -- Outcomes4Me Inc., the developer of the leading direct-to-patient, AI-driven platform transforming the cancer care...
HYDERABAD, India and VANCOUVER, BC, May 29, 2025 /PRNewswire/ -- Mapmygenome, an AI-driven leader in genomics and personalized health, announced...
NEW YORK, May 29, 2025 /PRNewswire/ -- AiCure, a leading AI and advanced data analytics company focused on transforming clinical...
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is...
Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in...
Parexel also launching a comprehensive Radiopharmaceuticals report at the meeting Onsite Parexel experts include recently appointed Chief Medical Officer and...